Ovation Science Inc.
On-going Pandemic Has Raised Importance for Employers to Implement Preventive Measures
VANCOUVER, BC and LAS VEGAS, NV / ACCESSWIRE / August 12, 2021 / (CSE:OVAT)(OTCQB:OVATF) - Ovation Science Inc. ("Ovation" or the "Company") is pleased to announce it has secured Pivot Protection Resource as a new national distributor for its non-alcohol hand sanitizer lotion, DermSafe®. Pivot Protection will be targeting their extensive business contacts across Canada. This Canadian PPE company, with vast experience in B2B including the healthcare industry, is committed to providing innovative products that are designed to aid in the protection of people in their work environment. With the pandemic continuing to spread due to the Delta variant, employers are looking for proven solutions to help employees feel safe about returning to work.
"There are many government campaigns and initiatives that are spreading awareness about the importance of preventive measures against the coronavirus as everyone returns to work," said Lyle Mills, President of Pivot Protection Resource. "We felt there was a great need for a non-alcohol hand sanitizer and one that had the science to back its effectiveness. We were therefore excited to learn about the unique benefits of DermSafe and look forward to making it available to our contacts across Canada. Pivot Protection Resource is committed to and excited about representing products that will truly make a difference."
"According to a recent New York Times article, on average we touch our face about 16 times per hour, and each time this exposes us to germs including the Delta variant," said Terry Howlett, President of Ovation Science. “The CDC (Center for Disease Control and Prevention) recommends we wash our hands for at least 20 seconds with soap or to use a hand sanitizer. People however are under the impression that alcohol hand sanitizers are all the same and will protect them against this virus. The fact is that many products do not have the recommended alcohol level of 70%. As well, people often do not use enough alcohol hand sanitizer for it to be effective. A whole ‘palm full' is the recommended amount or 3 ml., making a 60 ml hand sanitizer bottle last only 20 applications.” (Source: The New York Times: "The pandemic habit we should not break"; July 12, 2021). He continued, "DermSafe is different. It has no alcohol; it is proven effective against a host of germs and it requires only 1 ml per application so a 60 ml bottle lasts a whole month (2 applications/day). It is the perfect solution for employers looking for effective solutions when bringing their staff back safely to work."
DermSafe protects your hands against germs without the drying effects of alcohol. DermSafe uses 4% chlorhexidine gluconate (CHG), an ingredient used for over five decades in hospital scrub-up rooms. CHG has demonstrated long-term persistence in its ability to kill both gram-negative and gram-positive bacteria and viruses. Additionally, DermSafe is made with Invisicare® skin technology that helps the product bind to the skin, DermSafe has also been tested against a host of infectious germs, including the human coronavirus (Beta Coronavirus strain OC43, a surrogate for SARS-CoV-2); the virus that causes COVID-19 which was previously announced. The independent tests that were conducted showed a 99.97% reduction in the virus at 2 time points. Also, the Company previously announced that DermSafe is the only hand sanitizer that is a recipient of the Canadian Dermatology Review Panel's "Seal of Approval". This is an independent review by Canadian dermatologists.
The pandemic has raised awareness about the importance of personal hygiene including washing your hands frequently and using a hand sanitizer. This has led to increased sales worldwide, with hand sanitizer sales predicted to surpass USD 6.4 billion by 2027 according to Global Market Insights Inc.
To order from Pivot Protection visit https://pivotprotection.com/
For information about DermSafe and how to order visit https://dermsafe.com
For information about Ovation Science visit https://ovationscience.com.
Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its unique DermSafe® hand sanitizer and secondly its CBD/THC cannabis formulations including ARLO CBD Beauty and InVibe® MD ("health & wellness" line); all made with its patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees along with revenue from its own product sales. Ovation has its head office in Vancouver, BC Canada and its laboratory and operations in Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT and in the USA on the OTC Markets under the symbol OVATF. Visit our website www.ovationscience.com for more information.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance that the Company's DermSafe product will have increased sales,and that any additional exposure will result in sales. Although DermSafe has been tested against other envelope viruses there is no assurance that it will kill or be as effective against COVID-19 or the Delta variant. In addition, there is no assurance the Company's level of sales will continue or will not be negatively impacted by increased competition and recovery from the coronavirus pandemic. There is also no evidence it works better than alcohol. Other examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: strategies, potential sales, distribution and manufacturing of the Company's product as well as its effectiveness against COVID-19, the Company's ability to receive regulatory approval outside of Canada. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact:
INVESTOR RELATIONS:
Kin Communications: ovat@kincommunications.com
Phone: 604-684-6730 or Toll Free at 866-684-6730
FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Doreen McMorran: doreen@ovationscience.com
Phone: 604-283-0903 ext. 4
SOURCE: Ovation Science Inc.
View source version on accesswire.com:
https://www.accesswire.com/659389/Ovation-Science-Announces-Expanded-Distribution-of-DermSafe-Hand-Sanitizer
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
